Short description
CatalYm is a biotechnology company developing innovative immunotherapies for cancer patients.
Description
CatalYm is a biotechnology company committed to developing innovative immunotherapies for cancer patients. CatalYm has identified GDF-15 as a central regulator of the immune system in the tumor microenvironment and translates the therapeutic potential of neutralizing GDF-15 into meaningful clinical responses for patients with solid tumors. CatalYm’s CTL-002 program is poised to demonstrate clinical proof-of-concept in multiple solid tumor indications and has the potential to expand the treatment horizon for current and future immunotherapies.
Last funding
Nopepepe
Sign in for full access
Total funding
$$2020202
Sign in for full access
Location
Planegg, Bayern, Germany, Europe
Founded on
January 1, 2016
Non-profit?
No
Acquired?
No
Employees count
11-50
Revenue range
$7890 - 12340
Sign in for full access
Investors
Absolutely Noaccess, Nopepepe, Nopepepe, Absolutely Noaccess, Cannot Access, Uh Ohhhh, Noaccess, Noaccessforu, Uh Ohhhh
Sign in for full access
Founders
Jörg Wischhusen